Trinity Biotech, a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, has announced the development of CGM+, its flagship AI-native continuous glucose monitoring system. Currently in the later stages of device development, the platform represents a significant evolution from traditional glucose monitoring devices by integrating multiple biosensors within a single wearable unit.
The CGM+ platform distinguishes itself through its comprehensive approach to health monitoring. The device incorporates an ultra-thin, minimally invasive electrochemical glucose sensor alongside continuous monitoring capabilities for heart activity, body temperature, and physical activity. This multimodal data collection is optimized for real-time AI analysis, providing users and healthcare providers with contextual insights into metabolic and physiological health patterns.
Trinity Biotech's proprietary needle-free glucose sensor technology enables the collection of these expanded data points while maintaining a modular, user-friendly design. The company emphasizes that this approach reduces disposable components and waste while significantly lowering the cost of care compared to current market-leading products. The expanded data collection capabilities provide insights into essential metabolic factors including sleep patterns, stress levels, and physical activity impacts.
"CGM+ is not just a device—it's a proprietary data engine we are building for the AI health ecosystem," said John Gillard, CEO of Trinity Biotech. "We believe this technology can power the next wave of personalized, predictive, and preventative care—while opening up entirely new commercial pathways for Trinity Biotech, from device sales to AI-driven data services. It will also position us to compete well beyond traditional diagnostics, at the intersection of chronic disease management, digital health and consumer wellness."
The platform is engineered to support the healthcare industry's transition toward precision medicine and continuous real-world data collection. CGM+ combines glucose, cardiovascular, thermoregulation, and physical activity data to provide comprehensive multi-sensor intelligence. The device is designed to serve both regulated clinical workflows and consumer wellness applications, effectively bridging the gap between medical-grade monitoring and everyday health optimization.
As AI-based diagnostics, behavioral coaching, and chronic disease management become increasingly prevalent in healthcare, Trinity Biotech positions CGM+ as a critical enabler of these technologies. The platform's architecture supports integration with AI-native health applications, making it a foundational tool for the evolving digital health ecosystem.
Click here for the original news story.